Jan 1 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
HUTCHMED ANNOUNCES NDA ACCEPTANCE IN CHINA WITH PRIORITY REVIEW STATUS FOR ORPATHYS® AND TAGRISSO® COMBINATION IN LUNG CANCER PATIENTS WITH MET AMPLIFICATION AFTER PROGRESSION ON FIRST-LINE EGFR INHIBITOR THERAPY
HUTCHMED (CHINA) LTD - THIS ACCEPTANCE ALSO TRIGGERS A MILESTONE PAYMENT FROM ASTRAZENECA
Source text: ID:nGNX1YMGnt
Further company coverage: 0013.HK
((Reuters.Briefs@thomsonreuters.com;;))